Dottikon ES Holding AG

DESN

CH0582581713

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
233 ^CHF	+1.75%		+1.08%	+1.75%

2023	Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up	MT
2023	Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023	CI

Dottikon ES Plans Capital Increase

February 18, 2021 at 02:53 am EST

Dottikon Es Holding AG (SWX:DESN) said it plans capital increase to finance parts of expansion investments during next 7 years of around CHF 600 million.

Latest news about Dottikon ES Holding AG

Dottikon ES Posts Lower Fiscal H1 Net Income; Sales Up	Nov. 28	MT
Dottikon ES Holding AG Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 27	CI
Dottikon ES Free Float Rises Amid Share Sale by Majority Investor	23-06-16	MT
Dottikon ES' Majority Shareholder Kicks Off Share Sale	23-06-14	MT
Dottikon ES Holding AG: Under the radar	23-06-02
Dottikon ES Holding AG Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-31	CI
Dottikon ES Posts Higher FY23 Net Income; Net Sales Rise	23-05-31	MT
Dottikon Es Holding AG Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-29	CI
Swiss Chemicals Group Dottikon's Fiscal H1 Profit Jumps On Revaluation Of Deferred Tax Liabilities	22-11-29	MT
Switzerland's Dottikon Forecasts Higher FY23 Sales Amid 31% Growth in Fiscal H1	22-10-21	MT
Swiss Chemicals Group Dottikon Unveils Additional Measures To Cut Energy Consumption	22-10-13	MT
Global markets live: Credit Suisse, Telecom Italia, GSK, Apple, Boeing...	22-05-31
Dottikon Es Holding AG Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-31	CI
Swiss Chemicals Group Dottikon's FY22 Profit Climbs 13% As Net Sales, Order Volume Grow	22-05-31	MT
Certain Shares of Dottikon Es Holding AG are subject to a Lock-Up Agreement Ending on 14-DEC-2021.	21-12-13	CI
Dottikon Es Holding AG Reports Earnings Results for the Half Year Ended September 30, 2021	21-11-26	CI
Dottikon ES Fiscal H1 Profit Rises 13% as Sales Grow	21-11-26	MT
Dottikon Es Holding AG(SWX:DESN) added to S&P Global BMI Index	21-09-20	CI
Dottikon Es Holding AG(SWX:DESN) added to Swiss Performance Index (Price Return)	21-06-28	CI
Dottikon Es Holding Ag Reports Earnings Results for the Full Year Ended March 31, 2021	21-05-28	CI
Dottikon ES : Raises $214 Million Via Share Offering	21-03-10	MT
Dottikon ES : Books Fully Covered in Share Offering	21-03-08	MT
Dottikon ES : Core Shareholders Exercise Pre-Emptive Rights in Share Offering	21-03-05	MT
Dottikon ES : Plans $244 Million Capital Raise to Finance Expansion	21-02-26	MT
Dottikon ES Plans Capital Increase	21-02-18	CI

Dottikon ES Holding AG is a Switzerland-based holding company that specializes in hazardous chemistry and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industries. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The Company also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. It also held a 33.9%-stake in SYSTAG, System Technik AG.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Dottikon ES Holding AG: Under the radar

June 02, 2023 at 04:22 am EDT

More Strategies

Ratings for Dottikon ES Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

233

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DOTTIKON ES HOLDING AG	+1.75%	3.51B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Dottikon ES Holding AG

Equities

DESN

CH0582581713

Pharmaceuticals

Dottikon ES Plans Capital Increase

Latest news about Dottikon ES Holding AG

Chart Dottikon ES Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Dottikon ES Holding AG

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals